Further Tests Done on Avanafil: Impotency Correction Report
Further testing has been completed to evaluate the Avanafil impotency drug once again. A Phase 3 study has revealed some very positive results about usage of this medication.
The California-based VIVUS, Inc. pharmaceutical company is the one currently in charge of this recent Phase 3 Avanafil impotency drug clinical trial.
Trial Results
The results of this clinical trial named REVIVE TA-301 indicated that men were able to successfully have intercourse after 15 minutes of use. Men were also able to have successful intercourse even after six hours of use during this REVIVE TA-301 trial.
The Testing Environment
The environment where the REVIVE TA-301 trial was a controlled, placebo double-blind administered in a random format. It involved 650 men of all who had history of impotency (a.k.a. erectile dysfunction).
The Testing Process
First the men started out with four weeks of no treatment during the clinical trial. This is probably to see where each man was and how severe the problem was for them.
Then, each man was given a 50mg, 100mg, or 200 mg dosage for 12 weeks. Either that or they were given a placebo. The results were measured using the Erectile Function Domain score of the International Index of Erectile Function.
Along with that each participant was asked to complete a sexual encounter questionnaire. This lead to the knowledge that Avanafil was well tolerated and it had “very low incidence of side effects.”
Supposedly, it has had a lower side effect rate than that of Viagra, Cialis, or Levitra. This is quite a surprise and quite a new development for PDE5-inhibiting drugs. On the other hand, for most men who use these types of medications there is no problem.
Additional Testing
More testing are planned out for the future. One goal is to see how effective Avanafil is on diabetic men as well as men suffering from post-radical prostatectomy (prostate cancer surgery) impotency.
The Outlook
If Avanafil passes effectiveness and safety tests, it is a drug that could provide users with considerably less complications (side effects). It also is expected to last 50% longer than Viagra or Levitra.
It will take awhile though before enough testing has been done to satisfy the FDA. Once it is approved by the FDA, Avanafil will first gain approval in Europe by the EMEA.
In the mean time, eager patients will need to be patient-no put intended. That is the nature of getting impotency drugs approved. It takes time. Information for this short report was taken from news printed on June 8, 2010.